Hematocrit and Risk for Hypertension in Middle-Aged Japanese Male Office Workers

The association of hematocrit with development of hypertension over 9 years was studied in 784 hypertension-free Japanese men aged 40 to 59 years. The age-adjusted relative risk for hypertension above the borderline level and definite hypertension increased in a dose-dependent manner as hematocrit l...

Full description

Saved in:
Bibliographic Details
Published inIndustrial Health Vol. 39; no. 1; pp. 17 - 20
Main Authors NAKANISHI, Noriyuki, YOSHIDA, Hiroshi, OKAMOTO, Mitsuharu, NAKAMURA, Koji, UZURA, Sachiko, SUZUKI, Kenji, TATARA, Kozo
Format Journal Article
LanguageEnglish
Published Japan National Institute of Occupational Safety and Health 2001
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The association of hematocrit with development of hypertension over 9 years was studied in 784 hypertension-free Japanese men aged 40 to 59 years. The age-adjusted relative risk for hypertension above the borderline level and definite hypertension increased in a dose-dependent manner as hematocrit level increased (P for trend: 0.007 and 0.001, respectively). After controls for other potential factors of hypertension, the test for trend across increasing categories of hematocrit level remained as statistical significance for definite hypertension (P=0.015). The multivariate-adjusted relative risk for definite hypertension compared with less than 43.8% of hematocrit level was 1.29 [95% confidence interval (CI): 0.62-2.67] for 43.8 to 45.2% hematocrit level, 1.35 (95% CI: 0.62-2.95) for 45.3 to 46.3% hematocrit level, 1.96 (95% CI: 0.97-3.97) for 46.4 to 48.1% hematocrit level, and 2.06 (95% CI: 1.02-4.15) for 48.2% or more hematocrit level. These results suggest that hematocrit is closely associated with development of hypertension in middle-aged Japanese men.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ObjectType-Article-1
ObjectType-Feature-2
ISSN:0019-8366
1880-8026
DOI:10.2486/indhealth.39.17